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ABSTRACT: Mathematical models are an important tool in pharmaceutical formulations 
development, to evaluate in vitro and in vivo drug release processes and to optimize the design of 
new systems. Dome Matrix technology allows the combination of modules with different types of 
drugs, doses, and releases kinetics. This work aimed to design drug release systems based on Dome 
Matrix technology, with different swelling and erosi n properties, to obtain complex drug release 
profiles and analyze them with simple mathematical models. Most of the release profiles followed a 
sigmoid curve, with an inflection point corresponding to a change in the release rate behavior. The 
experimental data were fitted with a simple model recently developed, named the Dual Release 
model, which consists in the combination of a modifie  Korsmayer-Peppas model from the 
beginning to the inflection point and the Lumped model from there until the end. This approach 
allowed determining relevant pharmaceutical parameters, such as the maximum release rate and the 
dissolution efficiency, among others. The use of the Dual Release model and the pharmaceutical 
parameters that characterize the different Dome Matrix modules allows optimizing the choice of the 
composition and the configuration during the development of a drug delivery system. 
 




In 2006, Colombo and collaborators developed an innovative modular technology platform suitable 
for assemblage into drug delivery systems. Each module consists of a cylindrically shaped tablet, 
with one of the bases concave and the other convex1,2. Since the axial section of the modules 
appears as a cupola, such modular technology platform was named Dome Matrix. The individual 
modules are designed to allow the convex base of one module to be inserted into the concave base 
of another. This modular technology platform allows modifying the kinetics of drug release through 
the assembly of the modules containing the drug(s), constituting a single system for controlled drug 
release for oral administration (Figure 1)2,3.  
 
//Insert Fig. 1// 
 
A single Dome Matrix module has a comparable surface rea to that of a flat-based conventional 
tablet2. The shape of the modules facilitates the assembly of two or more units by stacking, thus 
obtaining multiple module systems. When the convex face of one module is stacked into the 
concave face of the adjacent one, the piled configuration is obtained; while the void configuration 
consists of a peculiar assembly formed by stacking two modules through their concave bases 
(Figure 1). This latter configuration is characteriz d by an inner space, providing the assembly with 
the potential to work as a floating drug delivery system and thus providing, after administration, 
gastroretention and site-specific drug release, assuring drug absorption in the upper part of the 
gastrointestinal (GI) tract. On the other hand, theassembly of two modules formulated as 
hydrophilic matrices, in a piled configuration reduces the available surface area for drug release 
more than the void configuration if compared to thesurface area of the two separated modules2. 
This implies that the piled configuration is potentially useful as a sustained-release drug vehicle, 
whereas the void configuration can be applied as a buoyant gastro-retentive dosage form. The void 
space in the assembly generates buoyancy forces that can keep the matrix afloat for as long as 8 
hours; then, erosion or disintegration process super ed s the floating behavior4,5  
Dome Matrix technology shows definite advantages as a drug delivery system when compared to 
traditional controlled-release tablets. It is such a versatile system that allows the combination of 
modules loaded with different types of incompatible drugs, different doses, and even providing 
multiple release kinetics in a single unit. The planned therapeutic regimen and the drug release 
kinetics can be adapted according to the disease sttus and the convenience of healthcare/patient 
management simply by changing the number and type of modules constituting the personalized 
system5-7.  
Mathematical models are an important tool to evaluate drug release processes both in vitro and in 
vivo and, in general, to optimize the design of new pharmaceutical drug delivery systems8. They 
also allow determining some important parameters related to the physicochemical phenomena (for 
example, drug diffusion coefficient)9 and of pharmaceutical relevance (such as the dissolution 
efficiency). It is very important to know how to use these equations to understand the different 
factors that affect the dissolution rate and how dissolution behaviors can vary and influence the 
efficiency or therapeutic regimen of patients. 
Since the Higuchi model10,11, various mathematical models were proposed to fit data from drug 
release profiles12, such as the semiempirical equation, called the power-law model, presented by 
Peppas and Sahlin13, or other models developed for specific drug delivery system geometries14-17. 
However, these models are usually useful to fit only the data up to 60% of the drug released over 
time. We recently developed a mathematical model, named the Lumped model, based on second-
order kinetics, that groups different transport step  involved in the drug release processes18,19. 
Although the Lumped model fits properly in vitro experimental data across the entire drug release 
profile, neither this nor the other models can fit da a following sigmoid profiles, where the release 
rate increases over time up to an inflection point a d decreases thereafter. In this regard, the 
cumulative Weibull function model20,21 was used to describe sigmoidal profiles of drug release over 
time, among other types of observed complex phenomea. However, important differences were 
observed in several studies between the experimental dat  and the values estimated by the Weibull 
function, mainly at the beginning (up to 10% of drug released) and at the end (after 70% of drug 
released) of the release profile. Considering this limitation, we developed a new model, named Dual 
Release model, able to fit experimental data from sigmoid profiles of the cumulative amount of 
drug release versus time with very low standard error (s≈1%) and correlation coefficient higher than 
0.9922. Moreover, the Dual Release model can be used to fit peculiar cases, such as experimental 
release data from profiles where the release rate incr ases constantly with respect to time until total 
drug release.  
Dome Matrix modules have been usually manufactured by tableting using cellulose derivatives or 
polyethylene oxide polymers4,5, since they form a monolithic system when the drug is dispersed into 
them and the powder tableted. Among cellulose derivatives, hypromellose or 
hydroxypropylmethylcellulose (HPMC) is used from 10% up to 80% w/w for controlled drug 
release in solid dosage form, and as a coating for tablets and pellets23-25. When in contact with the 
dissolution medium, HPMC matrix hydrates and swells forming a gel layer on the surface that 
moves towards the core26-28. Gel erosion takes place thereafter and may occur simultaneously with 
the subsequent phases of hydration and swelling of the matrix28. The swelling and erosion 
properties of a solid matrix made of HPMC have a strong influence on its drug release kinetics. 
In this work, HPMC matrices were designed based on D me Matrix technology containing 
riboflavin as a hydrophilic model drug. By varying the ratio of two HPMCs with different 
molecular weights and viscosities, modules with dissimilar swelling and erosion properties were 
obtained. Also, the release behavior of matrices of ingle configuration was compared with the 
presented by matrices of piled and void configurations prepared with two modules. In this way, 
complex drug release profiles were achieved, which were analyzed with simple mathematical 
models that allow to predict their behavior and explain the phenomena involved in the release 
process.  
 
MATERIALS AND METHODS 
Materials 
Riboflavin (Rb) (Universal®, Roche, batch number: UQ11022019), Methocel® (HPMC) CR 
premium K100LV and K15M with molecular weights of approximately 25 and 120 kDa29, 
respectively (Colorcon, Orpington, Eng, batch numbers: MM90041321K and NH16012N11), 
Lactose Spray Dried (90 – 150 µm, Chiesi, Parma, It.), Polyethylenglicol (PEG) 6000 (Hoechst AG. 
Werk Gendorf, Ger.), Kollidon® K25 (BASF, Ger, batch number: 09-8760) and magnesium tearate 
(Eigemann & Veronelli Spa., Mi, It., batch number: 24762) were used for matrices preparation. All 
other reactive and solvent used were p.a. quality and water and ethanol distilled. 
 
Manufacturing of Dome Matrix modules 
Five types of modules were prepared by direct compression using different mixtures of HPMC 
K15M and HPMC K100LV. Table 1 shows the percentage composition of the five modules types. 
Briefly, powders ground in a mortar and sieved through a 125 µm sieve were mixed in a Turbula 
mixer (WAB, Basel, Switzerland) for 30 min without lubricant. Then magnesium stearate was 
added and mixed for 5 min. The matrices were obtained by automatic direct compression in a single 
punch tableting machine (EKO Kosch, Berlin, Germany) provided with a special set of cylindrical 
punches of 7.4 mm diameter having the upper punch a convex surface and a lower concave punch. 
The compression force was between 20 and 30 kN in all cases. The final weight of the modules was 
110±5 mg containing 10 mg of riboflavin. 
Dome Matrices in piled and void configurations were p pared by assembling two modules. The 
piled configuration was obtained by inserting the convex base of one module into the concave base 
of the adjacent one and welding by ultrasound. To obtain a floating system, the void configuration 
was prepared by welding two modules with the concave bases facing each other2. In both cases, the 
welding of the assembled modules was performed using a Branson ultrasound machine (Branson 
Ultraschall, Dietzenbach, Germany) consisting of a concave punch shaped titanium sonotrode probe 
and a cylindrical die holding the matrices. The modules were stacked on the die and the resulting 
system was pressed with the sonotrode at 100-110 N, using the Time mode for 0.55 s (energy: 40-
70 J). Twenty soldered systems of each formulation were tested for resistance using the 
friabilometer operating at 25 rpm for 4 min, complying with the pharmacopoeial specification 
which accepts a maximum mean weight loss lower than1.0%30.  
 
//Insert Table 1// 
 
In vitro drug release studies 
The riboflavin release studies from the single modules and the two assembled configurations were 
performed in a USP dissolution apparatus 2 (Erweka DT6R, Heusenstamm, Germany) with paddle 
rotation at 75±1 rpm, using 900 ml of degassed simulated gastric fluid without pepsin (pH 1.2±0.5) 
as dissolution medium, at 37.0±0.5°C. The released riboflavin was quantified 
spectrophotometrically at 267 nm, using the corresponding calibration curve. 
 
Mathematical modeling of drug release profiles 
Riboflavin release profiles were analyzed by the Dual Release model, which allows fitting 
experimental data following sigmoid curves22. It consists of dividing the curve into two parts at the 
characteristic inflection point and applying a modified Korsmeyer-Peppas like model (Eq. 1) in the 
first part and a modified Lumped model (Eq. 2) in the second one. This model will be retaken and 
discussed in depth in the results and discussion section. 
 
  % =  +  × 
     (1) 
 
where c (%), d (% min-n) and n, are the model parameters and t (min) is the time. 
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 =  ×()×()      (2) 
 
where a (% min-1) and b (min-1) are the characteristic parameters of the model and tL is the lag time, 
which is the value of time obtained by extrapolation of the model for Mt%2 = 0. 
Using the mathematical equations proposed by the models it was possible to calculate different 
parameters of pharmaceutical relevance, such as the maximum release rate (RRmax), the time needed 
to release the 80% of the drug (t80%), the dissolution efficiency (DE), and the mean dissolution time 




Assays were performed by triplicate and data are presented as the mean ± the standard deviation (s). 
Regression and statistical analysis of the data were performed using Polymath 6.0 software 
(Polymath Software, Connecticut, USA).  
 
RESULTS AND DISCUSSION 
Mathematical modeling of drug release profiles 
The riboflavin release profiles from the Dome Matrix modules manufactured with different 
compositions (C1-C5) based on different HPMC proportions are shown in Figures 2a, 2b, and 2c, 
for the single modules, piled and void configurations, respectively. From the release profiles, it can 
be observed that an increasing proportion of the HPMC K15M allows for a prolongation of the drug 
release in all the cases.  
 
//Insert Fig. 2// 
 
Mathematical equations enable the quantitative interpretation of the values obtained from a drug 
release assay. They are important tools that allow to explain the behavior of drug formulations and 
to evaluate and compare them through by determining different pharmaceutical parameters.  
The steps in the process of drug release from a formulation based on a swellable polymer involve 
first the fluid absorption and matrix swelling; the subsequent drug dissolution and diffusion through 
the matrix, its erosion and finally the transfer of the drug from the drug dosage form surface of the 
form to the surrounding solution. During the first steps, the matrix absorbs the liquid solution and 
swells, opening its structure and therefore increasing the diffusivity as a function of time. The drug 
release rate increases with time until swelling and dissolution rates are of the same order of 
magnitude, after which the release rate begins to decrease. Therefore, the drug release profile will 
be different, depending on the rate of each step. 
The profiles of the percentage of riboflavin released versus time clearly showed an inflection point 
(ti) corresponding to a change in the release rate behavior, except maybe the ones belonging to the 
C1 composition, for which the ti could be identified after the 95% of drug release. Since most of the 
presented drug release profiles from the Dome Matrix assemblies follow a sigmoid curve, the 
possibility of analyzing the data with cumulative Weibull function was studied. However, this 
mathematical function did not present a good fitting for these curves, and even in some cases, the 
calculated data were far from those determined experimentally (the results obtained from the 
application of the Weibull function to the riboflavin release profiles are shown in the 
Supplementary Material). 
Rothstein et al. proposed a model that describes the drug release mechanism of a water-soluble 
agent from a spherical matrix16. The authors solved the differential equation using the finite element 
method. The solution of this complex mechanism for a 2:1 blend of 7.4 kDA PLGA and 60 kDA 
PLA shows a sigmoid profile of cumulative released fraction over time. However, it was not 
possible to obtain a simple analytical equation.  
In 2009 Lao et al. presented an analytical expression for the fraction of drug released as a function 
of time, based on a three-step mechanism15. The model equation is given by the sum of the solution 
of each step. The authors found a good correlation coefficient for the release of the hydrophobic 
drug paclitaxel release from bulk-degrading PLGA 53/47 films, which exhibits a sigmoid profile. 
However, the models based on multiple release mechanisms are very complex, many parameters 
need to be estimated beforehand and some programming sk lls are necessary to fit the model 
equation to experimental data. Furthermore, care must be taken in each particular case in the valid 
range of parameter values.  
Accounting for this situation, the Dual Release model, recently developed by our research group22 
can fit experimental data from release profiles following sigmoid curves (s in the order of 1% and 
correlation coefficients better than 0.995). Also, this model can fit experimental data from concave 
release profiles as shown by modules based on C1 composition. The sigmoid profiles have an 
inflection point where the first derivative respect to time (release rate) is maximum, and therefore, it 
is important to determine the inflection point time, which is possible with the proposed model. 
If the fluid uptake and swelling of the matrix are fast compared to the other steps, then the drug 
release profile will be a continuous curve with a mximum release rate at the initial time. The 
swelling phenomenon will not have any influence on the dissolution rate and the modified Lumped 
model (Eq. 2) will fit the experimental data with tL = 0. On the other hand, if fluid absorption and 
swelling play a major role in the process, the profile will have an inflection point where the 
mechanism of the drug release process changes. In the first part, the drug release rate increases up 
to the inflection point (Eq. 1) and then begins to decrease following the modified Lumped model 
(Eq. 2).  
Therefore, the full range of experimental data is covered by the Dual Release model, which is the 
combination of two equations given by Eq. 1 from the beginning of the drug release process to the 
time of the inflection point and by Eq. 2 from there to tF. It should be noted that the percentage of 
drug release at tF achieved in this study is 95% or higher. 
Table 2 shows the results obtained from the fitting of the experimental data using the Dual Release 
model proposed, and the theoretical release curves of the model can be observed in Figure 2 for the 
three configurations (continuous lines interpolating  release profiles). 
Table 2 shows the values of the model parameters, the correlation coefficient (R2), and the standard 
deviation (s) for each case, which is defined by Eq. 3: 
 
 = ()()      (3) 
 
where SSD is the sum of the squares of the differences between the experimental value and the one 
calculated by the model, and  is the number of samples taken in an experimental run. 
The correlation coefficient values (from 0.9901 to 0.9999) and standard deviations (from 0.08 to 
1.95) suggested a good fitting of the experimental data and supported the accuracy of the model. 
 
//Insert Table 2// 
 
The experimental data of the riboflavin release profiles following an inflection point were fitted by 
the modified Korsmayer-Peppas model13,33-35, described by Eq. (1), from the first experimental point 
up to the inflection point, with exponential parameter n higher than one. The mathematical fitting 
was made from the first experimental point taken (5 minutes in all cases) since either the release 
does not occur as soon as the matrix is contacted with the fluid because a lag period is required 
before the release process begins, or the concentratio  is too low to be detected by analytical 
methods. The exponent n is related to the release mechanism36. While values of 0.5 indicate pure 
Fickian diffusion, values between 0.5 and 1 are considered anomalous transport. On the other hand, 
exponent values greater than one indicate a Fickian release with a diffusion coefficient that changes 
over time.   
Besides, this model allows fitting the experimental d ta obtained from profiles that comply with the 
power law, in which a concave curve is followed over the entire time range, such as that observed 
for the Dome Matrix modules based on the composition C1 which have only HPMC K100LV. 
These modules presented a profile in which the first derivative respect to time increases until total 
release. This behavior is probably because, in the initial dissolution phase, the pores closest to the 
matrix surfaces can be quickly filled with water. In this way, rapid drug release can occur because 
the process of swelling and gelation of the matrix is very slow. Continuous hydration of the matrix 
is accompanied by dilution of the polymer chains in the gel layer, which leads to a continuous 
increase in the drug release rate. The modified Korsmeyer-Peppas model accounts for the 
mechanism of swelling, diffusion, and erosion of the matrix along with the entire range of the drug 
release profile. Losi et al. studied the swelling behavior of Dome Matrix drug delivery modules by 
high-resolution X-ray computed tomography37. For this purpose, they prepared Dome Matrix tables 
by direct compression of particles of near 130 μm size at 200 MPa. The authors observed that the 
expansion of the structure due to swelling caused th  detachment of particles from the matrix with 
time, and therefore the release rate increased constantly until finally, the module disintegrated 
completely. This phenomenon is expected to occur faster in matrices prepared with low viscosity 
HPMC, such as the based on the C1 composition, and agrees with their observed drug release 
profile. 
On the other hand, when the amount of HPMC K15M increases in the composition of the Dome 
Matrix modules, visual observations of the modules ba ed on C2, C3, C4, and C5 composition 
evidenced a noticeably thick and viscous gel layer with a slow erosion and a diffusion front near the 
swelling front. Although the more hydrated the gel, the less resistant it is to drug diffusion, this 
would also lead to an increase in the diffusion distance of the drug through the gel with a 
consequent deceleration in the drug release process, after an increase in the drug release rate 
before the inflection point. It is known that a rapid hydration rate is necessary followed by rapid 
gelation and a polymer/polymer coalescence so that a r e-controlling polymer forms a protective 
gelatinous layer around the matrix. This prevents the ablet from disintegrating immediately, 
resulting in the premature release of the drug.  
 
Release rate  
Useful information to evaluate the behavior of different systems in general, and of the Dome Matrix 
modules in this case in particular, is provided by the release rate (RR) and the maximum release rate 
(RRmax). Considering the release profiles following a sigmoid curve, the release rate initially 
increases continuously until reaching the time corresponding to the inflection point where it is 
maximum. Since the Dual Release model fits very well ith the experimental data from these 
profiles, it is possible to evaluate the rates and their maximum values in each case.  
From the beginning of the drug release until the inflection point, the data are fitted by Eq. 1, and 
then, the RR is given by Eq. 4:  
 
    =  ×  × 
()      (4) 
 
From the inflection point until tF, Eq. 2 is valid and the RR can be calculated from Eq. 5:  
 
    =  (×())     (5) 
 
Taking into account Eq. 5, the RRmax is found for the time corresponding to the inflection point (Eq. 
6): 
 
    =  (×())      (6)  
 
The values of RRmax calculated for the different Dome Matrix configurations and compositions are 
shown in Table 3. In the case of the profiles corresponding to the Dome Matrix modules based on 
the C1 composition, which do not present an inflection point and the whole range of experimental 
data is fitted by Eq. 1, since the RR increases continuously, the RRmax was determined for the time 
corresponding to a 95% of drug released.  
As it can be observed in Table 3, when the proportion of HPMC K15M is increased in the module's 
composition, the RRmax decreases for all the configurations studied, probably because its higher 
viscosity makes the structure more rigid. On the other hand, the Dome Matrix configuration 
influence the RRmax, being almost double for the single configuration c mpared to the void one, and 
even lower when the modules are assembled in the piled configuration, regardless of the 
composition. This behavior may be explained by the fact that the single module has almost twice 
the transfer surface area per unit volume than the o r two assembled modules. The initial surface-
exposed area per unit volume of the modules developed in this study were 17.40 and 10.95 cm-1 for 
the single unit and the piled configuration, respectiv ly, while it was 10.90 cm-1 for the void 
configuration, excluding the volume inside the assembl d modules. The difference of RRmax 
between the two assembled configurations is explained because the void configuration has an empty 
volume inside the two units while the piled one is formed by a compact body of the two units. 
Furthermore, the single module and the piled configuration have one convex and one concave 
surface exposed, while the void configuration has two convex surfaces exposed. Caccavo et al. 
showed that the erosion rate of convex surfaces is slightly higher than the concave surfaces because 
the first one is more accessible by the agitated meium38. 
 
//Insert Table 3// 
 
 
Parameters of pharmaceutical relevance 
Taking into account the good fitting of the model, several useful parameters that characterize the 
profiles of drug release platforms were estimated. These parameters allow a comparison between 
the formulations of a drug and to evaluate the influence of different variables on the release profiles.  
One of the most used and simple parameters is the time required to release a certain percentage of 
the drug (tX%), which is usually determined for 80% of the drug eleased (t80%).  
Another characteristic parameter of a pharmaceutic form is its dissolution efficiency (DE), which is 
defined by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
as the ratio between the area under the release profile up to a certain final time (tF), and the area of 
the rectangle described by 100% release at the sametF (Eq. 7). 
 
   = ! "#%  $
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For profiles presenting an inflection point and, therefore, a lag time, DE is given by Eq. 8: 
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Here, t1 is the time corresponding to the first experimental sample taken during the release study (5 
min in all cases).  
Replacing Eq. 1and 2 in Eq. 8 and solving the integrals, the DE can be calculated from Eq. 9: 
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In the case of the C1 modules based on HPMC K100LV, since the Eq. 1 fits the whole profile of the 
drug release, the DE is calculated from Eq. 10, which is obtained from Eq. 8 canceling the term of 
the integral of Mt%2. 
 
    = +×(% *)
,
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Finally, another interesting parameter that allows comparing release profiles is the mean dissolution 
time (MDTX%). According to the independent statistical methods
35, the following expression can be 
used to calculate the MDTX% (Eq. 11): 
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where tjm = (tj + tj-1)/2,  is the midpoint time between two samples and ΔM% is the additional 
amount of drug release between tj and tj-1. However, as we pointed out previously since the Dual 
Release model fits very well the experimental values, the MDTX% can be calculated from Eq. 12, 
which becomes Eq. 13 for the profiles that present ti and tL. 
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where Mt%(tX%) is the percentage of drug released at time X%. 
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In the case of Dome Matrix based on C1 composition, he MDTX% is given by Eq. 15: 
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The values of these parameters of pharmaceutical relevance are shown in Table 4. It can be 
observed that as the proportion of HPMC K15M polymer increased in the Dome Matrix 
composition, the release of the drug became more sustained over time, regardless of module 
configuration (single, void, or piled). Values of t80% of 154 min were found for modules based on 
pure HPMC K100LV with a single configuration and as high as 1190 min for pure HPMC K15M 
and piled configuration. The highest values of t80% were obtained for the piled configuration, 
followed by the void configuration and were lower fo the single one, regardless of the composition. 
On the other hand, the t80% value increases when the HPMC K15M is in a higher proportion in the 
composition of the module. As expected, the DE decreased and the MDTX% increased continuously 
as the amount of HPMC K100LV in the Dome Matrix composition was smaller, following the same 
behavior. 
 




A general Dual Release model that fits the experimental data of the release profiles of riboflavin 
from delivery systems based on the Dome Matrix technology was presented. This model is valid for 
a wide range of variables, such as different configurations of Dome Matrix modules and proportions 
of HPMC of different viscosity and swelling properti s. This model is based on the combination of 
the modified Korsmeyer-Peppas like the model from the process beginning to the inflection point of 
the drug release profile, and the modified Lumped model from the inflection point time up to the 
final process time, reaching values of percentage of drug release higher than 95%. The entire Dual 
Release model fit very well the experimental data from drug release profiles that followed sigmoid 
shaped curves with standard error near 1% and the regression coefficient higher than 0.995. 
Besides, it can also fit the drug release concave profile of modules prepared with low viscosity 
HPMC. The model proposed describes better the releas  profile than the cumulative Weibull 
function, which is analyzed in the Supplementary Materi ls. The Dual Release model allows 
obtaining a simple analytical equation of the release rate and can be used to analyze the effect of the 
different Dome Matrix configurations.  
The use of the Dual Release model and the pharmaceutical parameters that characterize the different 
Dome Matrix modules allows adapting the choice of the composition and the configuration to meet 
the requirements in the release performance of a drug elivery system. Therefore, mathematical 
evaluation of drug release kinetics adds value, ensuring the optimal design of pharmaceutical 
formulations as well as understanding release mechanisms through experimental verification. 
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Fig 1. Dome Matrix modules of riboflavin prepared by direct compression: single modules (a), piled 
(b) and void (c) configurations of two modules. 
Fig 2. Release profiles of riboflavin in simulated gastric fluid from Dome Matrix modules based on 
different HPMC proportions for single module (a), piled (b), and void (c) configurations. Symbols 
are the mean value of the experimental data and lines represent the theoretical release predictions, 
corresponding the dotted line to Eq.1 and the continuous line to Eq. 2. 
 
Table 1. Formulations composition (mg) 
Components C1  C2 C3 C4 C5 
Riboflavin 10.0 10.0 10.0  10.0  10.0  
HPMC K15M 0 10.0 20.0 30.0 40.0 
HPMC K100LV 40.0 30.0 20.0 10.0 0 
Lactose 49.8 49.8 49.8 49.8 49.8 
PEG 6000 5.0 5.0 5.0 5.0 5.0 
PVP K25 5.0 5.0 5.0 5.0 5.0 
Mg Stearate   0.2 0.2 0.2 0.2 0.2 
 
 
Table 2. Dual Release model parameters, inflection point (ti), lag time (tL), correlation coefficients 
(R2) and standard deviation (s) for each Dome Matrix module configuration and the different 
compositions studied 















C1 -0.672 0.25974 1.1375 0.9996 0.43 -- -- -- -- -- -- 
C2 2.2827 0.03057 1.4877 0.9982 0.54 1.24734 0.00876 120 75 0.9936 1.95 
C3 1.0524 0.07848 1.1856 0.9999 0.08 0.50186 0.00306 120 65 0.9994 0.61 
C4 1.3972 0.02816 1.3502 0.9997 0.17 0.36761 0.00239 180 72 0.9971 1.18 
C5 3.3304 0.03672 1.2643 0.9994 0.14 0.24068 0.00126 140 37 0.9982 1.07 
Void configuration 
C1 -2.620 0.13082 1.1421 0.9985 1.19 -- -- -- -- -- -- 
C2 1.5773 0.03926 1.2476 0.9992 0.67 2.59601 0.02248 420 336 0.9901 1.04 
C3 0.5711 0.03320 1.2610 0.9995 0.22 0.19968 0.00065 233 50 0.9940 1.82 
C4 -0.228 0.04573 1.1696 0.9993 0.26 0.15168 0.00043 267 42 0.9985 0.85 
C5 1.7399 0.02366 1.2305 0.9989 0.13 0.11354 0.00029 180 42 0.9973 1.47 
Piled configuration 
C1 -1.907 0.25817 1.0356 0.9994 0.71 -- -- -- -- -- -- 
C2 0.9904 0.04198 1.2073 0.9971 0.87 0.57202 0.00461 360 200 0.9983 0.57 
C3 0.1708 0.03552 1.2254 0.9977 0.48 0.17296 0.00068 241 47 0.9972 1.16 
C4 0.8731 0.01926 1.2738 0.9996 0.16 0.12462 0.00039 295 50 0.9994 0.52 
C5 2.9303 0.04036 1.0999 0.9996 0.12 0.08550 0.00023 271 0 0.9999 0.22 
 






Single Void  Piled  
C1 0.604a 0.340a 0.328a 
C2 0.642 0.311 0.190 
C3 0.368 0.159 0.135 
C4 0.232 0.126 0.104 
C5  0.189 0.105 0.076 
a For 95% of drug released 
 
Table 4. Characteristic pharmaceutical parameters for the different configurations and compositions 























C1 154 43.8 81.4 285 20.5 157.8 260 25.5 134.9 
C2 222 57.9 114.9 437 27.6 239.3 593 28.0 282.3 
C3 377 39.4 178.3 592 23.7 289.5 724 20.6 340.0 
C4 530 30.7 238.7 725 19.6 352.5 905 15.5 433.5 
C5  608 27.9 266.3 928 15.6 448.5 1190 14.8 545.3 
a For C2, C3, C4, and C5 DE were calculated for t = 350 min, while for C1,  it was calculated for t = 
180 min. 
 




